MBX Biosciences (MBX) Total Liabilities (2023 - 2026)

MBX Biosciences has disclosed Total Liabilities across 4 years of filings, most recently posting $14.9 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $14.9 million, up 42.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.9 million (up 42.28% YoY), and the FY2025 annual result was $15.9 million, up 43.52% from the prior year.
• Total Liabilities came in at $14.9 million for Q1 2026 at MBX Biosciences, down from $15.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $97.9 million in Q2 2024 to a low of $4.3 million in Q4 2023.
• The 4-year median for Total Liabilities is $12.5 million (2025), against an average of $30.8 million.
• Across the five-year window, Total Liabilities jumped 158.52% in 2024 and sank 87.45% in 2025, its largest moves.
• MBX Biosciences' Total Liabilities stood at $4.3 million in 2023, then soared by 158.52% to $11.1 million in 2024, then surged by 43.52% to $15.9 million in 2025, then slipped by 6.13% to $14.9 million in 2026.
• The last three Total Liabilities figures came in at $14.9 million (Q1 2026), $15.9 million (Q4 2025), and $12.5 million (Q3 2025), per Business Quant data.